StockNews.AI
GH
StockNews.AI
173 days

New Guardant Health/Harris Poll Survey Highlights Patient Fear and Anxiety as Major Barriers to Colorectal Cancer Screening, but Blood Test Option Offers Hope for Change

1. 90% of physicians worry about patients not completing CRC screenings. A blood test could improve these rates.

2m saved
Insight
Article

FAQ

Why Bullish?

Increased screening rates via a blood test can enhance revenue, reflecting similar trends in successful product launches by companies in the health tech space.

How important is it?

The article focuses on issues that directly relate to Guardant's market potential and its product relevance in oncology.

Why Long Term?

Long-term benefits may arise from sustained improvements in CRC screening compliance and increased adoption of Guardant's test products.

Related Companies

DGXLHQGEN
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of the second annual “Closing the Gap: CRC Screening Insights” survey, which showed that nine out of ten physicians surveyed are concerned about the percentage of their patients who do not complete colorectal cancer (CRC) screening. In many cases, this is due to patient fear and anxiety, but a blood test option offers hope to increase screening rates. Conduct.

Related News